Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 1/20 | 0.44 |
| ▸ | AOC2 | O75106 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012533 | 1.00 | INPP5A (0.44) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL23160212 | 1.00 | INPP5A (0.44) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL6962289 | 0.98 | INPP5A (0.42) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL27984591 | 0.91 | INPP5A (0.38) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL26695944 | 0.88 | INPP5A (0.41) | INPP5AAOC2MAOAKAT8 | |
| SCHEMBL3352759 | 0.86 | INPP5A (0.47) | INPP5AAOC2MAOAAKT1PIK3CA | |
| SCHEMBL15732885 | 0.81 | — | — | |
| SCHEMBL9050598 | 0.79 | AOC2 (0.32) | AOC2MAOA | |
| SCHEMBL30140447 | 0.79 | AOC2 (0.32) | AOC2MAOA | |
| SCHEMBL6964526 | 0.78 | AOC2 (0.35) | AOC2MAOAAKT1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | claimed |
| CN-119638682-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638681-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638680-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-116323598-B | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-114539229-B | Pyrimidine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-113939515-B | Compositions and methods for treating KIT and PDGFRA mediated diseases | 缆图药品公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118201911-A | Compounds and their use as GPR183 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-113072476-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117425660-A | Aromatic heterocyclic compound, intermediate thereof, pharmaceutical composition and application | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| EP-2467378-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG Life Sciences Ltd (KR) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010093191-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | WO | disclosed |
| US-7189741-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA S.A. (ES) | 2007-03-13 | — | — | US | disclosed |
| EP-1330453-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2006-03-29 | — | — | EP | disclosed |
| US-20040116471-A1 | Indolylpiperidine derivatives as antihistaminic aand antiallergic agents | ALMIRALL PRODESFARMA S.A. (ES) | 2004-06-17 | — | — | US | disclosed |
| EP-1330453-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036589-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | MAP3K20, MAP3K15, MAP3K1 | INPP5A 998/4885AOC2 4495/4885MAOA 4153/4885 |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | INPP5A 998/4885AOC2 4495/4885MAOA 4153/4885 |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | XDH, PNPO, AOX1 | INPP5A 1247/4885AOC2 18/4885MAOA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.